Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06580145 · ClinicalTrials.gov registry record · Phase 2
Leucine in Midlife Depression
A Phase 2 study of Major Depression, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT06580145 is a Phase 2 study of Major Depression that is actively recruiting participants, run by Emory University. The registered enrollment target is 75 participants, below the 325-participant average among 28 other Major Depression trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06580145, a Phase 2 study of Major Depression, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
The study aims to investigate the effects of a 6-week leucine challenge on brain chemistry, connectivity, and behavior in people with midlife depression. The researchers will compare the leucine and an active comparator arm (lysine) for 6 weeks.
Conditions Studied
Interventions
- DRUG L-leucine
- DRUG L-lysine
Study Locations (1)
Georgia
- Emory University Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2029-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06580145
The ClinicalTrials.gov registry entry for NCT06580145 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 325-participant average among 28 other Major Depression trials with a reported enrollment target (77% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depression appearing as the primary indexed condition, and to 2 interventions - of which L-leucine is the first listed.
NCT06580145 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06580145 about?
NCT06580145 is a clinical study titled "Leucine in Midlife Depression". The study aims to investigate the effects of a 6-week leucine challenge on brain chemistry, connectivity, and behavior in people with midlife depression. The researchers will compare the leucine and an active comparator arm (lysine) for 6 weeks.
What is the current status of trial NCT06580145?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2025-02-01. Estimated completion is 2029-06.
What conditions does trial NCT06580145 study?
This clinical trial studies the following conditions: Major Depression.
What interventions are being tested in trial NCT06580145?
The interventions under investigation include: L-leucine (DRUG), L-lysine (DRUG).
Who is sponsoring clinical trial NCT06580145?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06580145 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine Alcohol (in Treatment-Resistant Depression)
RECRUITING · Phase 2
-
Lexapro and Pramipexole and to Treat Major Depression
COMPLETED · Phase 2
-
Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder
COMPLETED · Phase 2
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
University of Iowa Interventional Psychiatry Service Patient Registry
RECRUITING
-
NIMH Rhythms and Blues Study: A Prospective Natural History Study of Motor Activity, Mood States, and Bipolar Disorder
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.